These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 18443126

  • 21. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S, De Luca A, Villani P, Bacarelli A, Ragazzoni E, Regazzi M, Cauda R, Navarra P.
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [Abstract] [Full Text] [Related]

  • 22. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C, BMS AI424-043 Study Group.
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [Abstract] [Full Text] [Related]

  • 23. HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.
    Hobbs CV, Voza T, Coppi A, Kirmse B, Marsh K, Borkowsky W, Sinnis P.
    J Infect Dis; 2009 Jan 01; 199(1):134-41. PubMed ID: 19032102
    [Abstract] [Full Text] [Related]

  • 24. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, CASTLE Study Team.
    Lancet; 2008 Aug 23; 372(9639):646-55. PubMed ID: 18722869
    [Abstract] [Full Text] [Related]

  • 25. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
    Antivir Ther; 2007 Aug 23; 12(5):825-30. PubMed ID: 17713166
    [Abstract] [Full Text] [Related]

  • 26. Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice.
    Pouvelle B, Farley PJ, Long CA, Taraschi TF.
    J Clin Invest; 1994 Jul 23; 94(1):413-7. PubMed ID: 7913713
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A.
    AIDS Res Hum Retroviruses; 2006 Aug 23; 22(8):749-56. PubMed ID: 16910830
    [Abstract] [Full Text] [Related]

  • 28. Improved efficacy of doxycycline in liposomes against Plasmodium falciparum in culture and Plasmodium berghei infection in mice.
    Rajendran V, Singh C, Ghosh PC.
    Can J Physiol Pharmacol; 2018 Nov 23; 96(11):1145-1152. PubMed ID: 30075085
    [Abstract] [Full Text] [Related]

  • 29. Fitness of drug-resistant malaria parasites.
    Walliker D, Hunt P, Babiker H.
    Acta Trop; 2005 Jun 23; 94(3):251-9. PubMed ID: 15845348
    [Abstract] [Full Text] [Related]

  • 30. Antimalarial drugs clear resistant parasites from partially immune hosts.
    Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ.
    Antimicrob Agents Chemother; 2001 Oct 23; 45(10):2897-901. PubMed ID: 11557487
    [Abstract] [Full Text] [Related]

  • 31. In vitro and in vivo antimalarial activities of T-2307, a novel arylamidine.
    Kimura A, Nishikawa H, Nomura N, Mitsuyama J, Fukumoto S, Inoue N, Kawazu S.
    Antimicrob Agents Chemother; 2012 Apr 23; 56(4):2191-3. PubMed ID: 22252809
    [Abstract] [Full Text] [Related]

  • 32. Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.
    Sonoiki E, Nsanzabana C, Legac J, Sindhe KM, DeRisi J, Rosenthal PJ.
    Antimicrob Agents Chemother; 2017 Jan 23; 61(1):. PubMed ID: 27821443
    [Abstract] [Full Text] [Related]

  • 33. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
    Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF, AIDS Clinical Trials Group Protocol (ACTG 378) Study Team.
    Clin Pharmacol Ther; 2003 May 23; 73(5):406-16. PubMed ID: 12732841
    [Abstract] [Full Text] [Related]

  • 34. Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro.
    Buckling A, Ranford-Cartwright LC, Miles A, Read AF.
    Parasitology; 1999 Apr 23; 118 ( Pt 4)():339-46. PubMed ID: 10340323
    [Abstract] [Full Text] [Related]

  • 35. Chloroquine-resistant Plasmodium falciparum: now in Pakistani Punjab.
    Fox E, Khaliq AA, Sarwar M, Strickland GT.
    Lancet; 1985 Jun 22; 1(8443):1432-5. PubMed ID: 2861372
    [Abstract] [Full Text] [Related]

  • 36. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C, Frank I.
    Lancet; 2008 Aug 23; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract] [Full Text] [Related]

  • 37. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM, Robidou P, Jaillon P.
    Ther Drug Monit; 2005 Apr 23; 27(2):186-92. PubMed ID: 15795650
    [Abstract] [Full Text] [Related]

  • 38. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum.
    Adovelande J, Delèze J, Schrével J.
    Biochem Pharmacol; 1998 Feb 15; 55(4):433-40. PubMed ID: 9514077
    [Abstract] [Full Text] [Related]

  • 39. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.
    AIDS; 2005 Jan 28; 19(2):153-62. PubMed ID: 15668540
    [No Abstract] [Full Text] [Related]

  • 40. The potentiating action of tetrandrine in combination with chloroquine or qinghaosu against chloroquine-sensitive and resistant falciparum malaria.
    Ye ZG, Van Dyke K, Castranova V.
    Biochem Biophys Res Commun; 1989 Dec 15; 165(2):758-65. PubMed ID: 2688645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.